EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network

Gabriele Gugliotta, Mario Annunziata, Isabella Capodanno, Davide Rapezzi, Immacolata Attolico, Marianna Caramella, Iolanda D Vincelli, Antonella R Rossi, Mario Tiribelli, Alessandra Malato, Michele Cimminiello, Vincenzo Accurso und 25 weitere

Clinical Lymphoma Myeloma and Leukemia · 2026-10 · 26 (10) · e1211-e1217

DOI: 10.1016/j.clml.2026.07.011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-10. Verfasst von Gabriele Gugliotta und 36 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology "Seràgnoli", IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Dasatinib, Pyrimidines, Leukemia, Myeloid, Chronic-Phase. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Limited information is available on the management and outcome of chronic myeloid leukemia (CML) patients who are resistant to first-line treatment with a second-generation tyrosine kinase inhibitor (2G-TKI). PATIENTS AND METHODS: We conducted a multicenter, real-world, retrospective analysis on 69 chronic phase (CP) CML patients who switched to second-line treatment in case of failure (according to the European LeukemiaNet 2020 recommendations) after first-line nilotinib or dasatinib. RESULTS: The median time to switch to second-line therapy was 15 months, and ponatinib was the most frequently used TKI (68%). As best molecular response (MR), 78% of patients achieved a BCR::ABL1IS transcript level

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsDasatinibPyrimidinesLeukemia, Myeloid, Chronic-PhaseDrug Resistance, NeoplasmHumansFemaleRetrospective StudiesMaleMiddle AgedAgedItalyAdultAged, 80 and over

Stichwörter der Autor:innen

Chronic myeloid leukemiaFailurePonatinibSequential treatmentTyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsnilotinibDasatinibPyrimidines

Autor:innen und Institutionen

  • Institute of Hematology "Seràgnoli", IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
  • Hematology Unit, Cardarelli Hospital, Naples, Italy.
  • Hematology Unit, Azienda Unità Sanitaria Locale - IRCCS, Reggio Emilia, Italy.
  • S.C. Ematologia, Cuneo, Italy.
  • Hematology and Stem cell Transplantation Unit, Bari, Italy.
  • SC Hematology, Niguarda "Ca Granda" Hospital, Milan, Italy.

Zitieren

APA

Gugliotta, G., Annunziata, M., Capodanno, I., Rapezzi, D., Attolico, I., Caramella, M., Vincelli, I. D., Rossi, A. R., Tiribelli, M., Malato, A., Cimminiello, M., Accurso, V., Bonifacio, M., Galimberti, S., Loglisci, G., Abruzzese, E., Bocchia, M., Gozzini, A., Bergamaschi, M., …, & Stagno, F. (2026). Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network. Clinical Lymphoma Myeloma and Leukemia, 26(10), e1211-e1217. https://doi.org/10.1016/j.clml.2026.07.011

Vancouver

Gugliotta G, Annunziata M, Capodanno I, Rapezzi D, Attolico I, Caramella M, et al. Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network. Clinical Lymphoma Myeloma and Leukemia. 2026;26(10):e1211-e1217. doi:10.1016/j.clml.2026.07.011

BibTeX
@article{Gugliotta2026,
  author = {Gugliotta, Gabriele and Annunziata, Mario and Capodanno, Isabella and Rapezzi, Davide and Attolico, Immacolata and Caramella, Marianna and Vincelli, Iolanda D and Rossi, Antonella R and Tiribelli, Mario and Malato, Alessandra and Cimminiello, Michele and Accurso, Vincenzo and Bonifacio, Massimiliano and Galimberti, Sara and Loglisci, Giuseppina and Abruzzese, Elisabetta and Bocchia, Monica and Gozzini, Antonella and Bergamaschi, Micaela and Miggiano, Maria C and Tafuri, Agostino and Sanpaolo, Grazia and Scortechini, Anna R and Crugnola, Monica and Luzi, Debora and Luciano, Luigiana and Binotto, Gianni and Latagliata, Roberto and Castagnetti, Fausto and Allegra, Alessandro and Specchia, Giorgina and Markovic, Uros and Rosti, Gianantonio and Foà, Robin and Saglio, Giuseppe and Breccia, Massimo and Stagno, Fabio},
  title = {Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {10},
  pages = {e1211--e1217},
  doi = {10.1016/j.clml.2026.07.011}
}
Kostenlos starten →